Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
OTCPK:REPR's Cash-to-Debt is ranked higher than
93% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. OTCPK:REPR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:REPR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.72 Max: No Debt
Current: No Debt
Equity-to-Asset 0.82
OTCPK:REPR's Equity-to-Asset is ranked higher than
83% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. OTCPK:REPR: 0.82 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:REPR' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.85  Med: 0.42 Max: 0.86
Current: 0.82
-0.85
0.86
Piotroski F-Score: 4
Altman Z-Score: 15.11
Beneish M-Score: -1.64
WACC vs ROIC
-4.22%
-15.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % -5.99
OTCPK:REPR's Operating Margin % is ranked lower than
68% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.15 vs. OTCPK:REPR: -5.99 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:REPR' s Operating Margin % Range Over the Past 10 Years
Min: -5.99  Med: 12.64 Max: 24.28
Current: -5.99
-5.99
24.28
Net Margin % -4.35
OTCPK:REPR's Net Margin % is ranked lower than
66% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. OTCPK:REPR: -4.35 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:REPR' s Net Margin % Range Over the Past 10 Years
Min: -4.35  Med: 8.72 Max: 29.98
Current: -4.35
-4.35
29.98
ROE % -7.83
OTCPK:REPR's ROE % is ranked lower than
70% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.37 vs. OTCPK:REPR: -7.83 )
Ranked among companies with meaningful ROE % only.
OTCPK:REPR' s ROE % Range Over the Past 10 Years
Min: -7.83  Med: 18.36 Max: 639.38
Current: -7.83
-7.83
639.38
ROA % -6.47
OTCPK:REPR's ROA % is ranked lower than
68% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. OTCPK:REPR: -6.47 )
Ranked among companies with meaningful ROA % only.
OTCPK:REPR' s ROA % Range Over the Past 10 Years
Min: -6.47  Med: 12.94 Max: 57.04
Current: -6.47
-6.47
57.04
ROC (Joel Greenblatt) % -25.86
OTCPK:REPR's ROC (Joel Greenblatt) % is ranked lower than
73% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.96 vs. OTCPK:REPR: -25.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:REPR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -26.65  Med: 44.03 Max: 95.45
Current: -25.86
-26.65
95.45
3-Year Revenue Growth Rate 11.10
OTCPK:REPR's 3-Year Revenue Growth Rate is ranked higher than
77% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. OTCPK:REPR: 11.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:REPR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.9  Med: 14.4 Max: 26.2
Current: 11.1
-9.9
26.2
GuruFocus has detected 3 Warning Signs with Repro-Med Systems Inc $OTCPK:REPR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:REPR's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with REPR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:AMEX:DXR, WAR:MMD, NAS:VLRX, AMEX:RVP, NAS:BMRA, OTCPK:STXS, NAS:CASM, OTCPK:UEEC, OTCPK:NEPH, NAS:DXTR, NAS:PDEX, AMEX:ISR, NAS:ATEC, NAS:SKLN, LSE:AKR, OTCPK:ECIA, OTCPK:PEYE, NAS:SSKN, NAS:NURO, OTCPK:RSCF » details
Headquarter Location:USA
Repro-Med Systems Inc designs, manufactures and markets proprietary medical devices for the ambulatory infusion market and emergency medical applications.

Repro-Med Systems Inc was incorporated in the State of New York in March of 1980. The Company designs, manufactures and markets proprietary medical devices mainly for emergency medical applications and ambulatory infusion therapy. These products are regulated by the FDA. Its development and marketing focus are concentrated on the RES-Q-VAC(R) and the FREEDOM60(R) products. The FREEDOM60 uses 'engine' to create a constant pressure drive system. FREEDOM60(R) uses rate-controlled tubing with standard slide clamp and luer-lock connector on the patient end. Proprietary technology Employed in the FREEDOM60 uses constant pressure to administer drugs. FREEDOM60 avoids an important problem faced by electronic pumps currently on the market which Employ constant flow mechanisms that result in potentially dangerous, high pressures placed on indwelling catheters or under the skin. The Freedom60 Syringe Infusion Pump is designed for ambulatory medication infusions. The Company also designed and manufactured the Freedom60-FM, an enhanced version of the Freedom60 which contains an electronic flow monitor system that provides occlusion and end of infusion alarm. The Freedom60 use for Primary Immune Deficiency by injecting immune globulin under the skin as a subcutaneous administration continued to increase usage during the past year. This method has provided patients with improved quality of life with much fewer unpleasant side effects over the traditional intravenous route. The RES-Q-VAC(R) Emergency Airway Suction System is a lightweight, portable, hand-operated suction device that removes fluids from a patient's airway by attaching the RES-Q-VAC(R) pump to various proprietary sterile and non-sterile single-use catheters sized for adult and pediatric suctioning. The Company has introduced new, updated features including the FSP filter, new pediatric connectors, new graduated canister, new adult catheters, and new convenient carry pouch. It is also available with a flexible, portable LED white light source, which is attached to the top of the canister system and provides illumination for the medical professional during nighttime or low light conditions. The Company offers its products directly to large national accounts and emergency medical device distributors, as well as to regional distributors in the hospital respiratory care market.

Top Ranked Articles about Repro-Med Systems Inc

Insider Buys Repro-Med Systems Director buys 136,248 shares
Director and 10% owner of Repro-Med Systems, Joseph Manko Jr., purchased 136,248 shares of Repro-Med Systems (REPR) in late September, according to a Form 4 filing with the Securities and Exchange Commission. The purchase came in two transactions. Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.74
REPR's PB Ratio is ranked higher than
59% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.29 vs. REPR: 2.74 )
Ranked among companies with meaningful PB Ratio only.
REPR' s PB Ratio Range Over the Past 10 Years
Min: 1.09  Med: 2.42 Max: 58
Current: 2.74
1.09
58
PS Ratio 2.07
REPR's PS Ratio is ranked higher than
73% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.24 vs. REPR: 2.07 )
Ranked among companies with meaningful PS Ratio only.
REPR' s PS Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.32 Max: 3.12
Current: 2.07
0.62
3.12
EV-to-EBIT -20.72
REPR's EV-to-EBIT is ranked lower than
99.99% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.41 vs. REPR: -20.72 )
Ranked among companies with meaningful EV-to-EBIT only.
REPR' s EV-to-EBIT Range Over the Past 10 Years
Min: -104.1  Med: 6.8 Max: 54.2
Current: -20.72
-104.1
54.2
EV-to-EBITDA -33.71
REPR's EV-to-EBITDA is ranked lower than
99.99% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.62 vs. REPR: -33.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
REPR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1110.5  Med: 6.05 Max: 109.6
Current: -33.71
-1110.5
109.6
EV-to-Revenue 1.32
REPR's EV-to-Revenue is ranked higher than
79% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.43 vs. REPR: 1.32 )
Ranked among companies with meaningful EV-to-Revenue only.
REPR' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 1.2 Max: 3.7
Current: 1.32
0.4
3.7
Shiller PE Ratio 19.00
REPR's Shiller PE Ratio is ranked higher than
86% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.16 vs. REPR: 19.00 )
Ranked among companies with meaningful Shiller PE Ratio only.
REPR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 12.33  Med: 20 Max: 45
Current: 19
12.33
45
Current Ratio 7.64
REPR's Current Ratio is ranked higher than
79% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. REPR: 7.64 )
Ranked among companies with meaningful Current Ratio only.
REPR' s Current Ratio Range Over the Past 10 Years
Min: 0.71  Med: 2.75 Max: 9.6
Current: 7.64
0.71
9.6
Quick Ratio 6.18
REPR's Quick Ratio is ranked higher than
80% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. REPR: 6.18 )
Ranked among companies with meaningful Quick Ratio only.
REPR' s Quick Ratio Range Over the Past 10 Years
Min: 0.19  Med: 1.06 Max: 7.47
Current: 6.18
0.19
7.47
Days Inventory 94.56
REPR's Days Inventory is ranked higher than
72% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.43 vs. REPR: 94.56 )
Ranked among companies with meaningful Days Inventory only.
REPR' s Days Inventory Range Over the Past 10 Years
Min: 81.94  Med: 146.14 Max: 211.09
Current: 94.56
81.94
211.09
Days Sales Outstanding 56.41
REPR's Days Sales Outstanding is ranked higher than
76% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. REPR: 56.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
REPR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.23  Med: 52.16 Max: 73.22
Current: 56.41
40.23
73.22
Days Payable 21.56
REPR's Days Payable is ranked higher than
56% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. REPR: 21.56 )
Ranked among companies with meaningful Days Payable only.
REPR' s Days Payable Range Over the Past 10 Years
Min: 14.24  Med: 29.52 Max: 138.7
Current: 21.56
14.24
138.7

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.00
REPR's 3-Year Average Share Buyback Ratio is ranked higher than
67% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.00 vs. REPR: -1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
REPR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15.3  Med: -1.2 Max: 1.2
Current: -1
-15.3
1.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.20
REPR's Price-to-Net-Cash is ranked higher than
76% of the 58 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.97 vs. REPR: 10.20 )
Ranked among companies with meaningful Price-to-Net-Cash only.
REPR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 10.25 Max: 19.5
Current: 10.2
0
19.5
Price-to-Net-Current-Asset-Value 3.40
REPR's Price-to-Net-Current-Asset-Value is ranked higher than
76% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.23 vs. REPR: 3.40 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
REPR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 3.25 Max: 45
Current: 3.4
0
45
Price-to-Tangible-Book 3.00
REPR's Price-to-Tangible-Book is ranked higher than
66% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.71 vs. REPR: 3.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
REPR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.5  Med: 3.06 Max: 70
Current: 3
1.5
70
Price-to-Intrinsic-Value-Projected-FCF 2.22
REPR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
65% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.25 vs. REPR: 2.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
REPR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 1.3 Max: 8.5
Current: 2.22
0
8.5
Price-to-Median-PS-Value 1.59
REPR's Price-to-Median-PS-Value is ranked higher than
50% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. REPR: 1.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
REPR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1 Max: 2.25
Current: 1.59
0
2.25
Earnings Yield (Greenblatt) % -4.82
REPR's Earnings Yield (Greenblatt) % is ranked lower than
77% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. REPR: -4.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
REPR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -14.3  Med: 10.7 Max: 34.9
Current: -4.82
-14.3
34.9
Forward Rate of Return (Yacktman) % -14.63
REPR's Forward Rate of Return (Yacktman) % is ranked lower than
91% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.23 vs. REPR: -14.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
REPR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -14.63  Med: 4.3 Max: 33.8
Current: -14.63
-14.63
33.8

More Statistics

Revenue (TTM) (Mil) $12.29
EPS (TTM) $ -0.02
Beta-1.07
Short Percentage of Float0.00%
52-Week Range $0.34 - 0.59
Shares Outstanding (Mil)37.83
» More Articles for OTCPK:REPR

Headlines

Articles On GuruFocus.com
Insider Buys Repro-Med Systems Oct 04 2016 

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}